ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

DCT Board Sends Message On Cutting Grants to Extend Paylines, Then Tries To Take It Back

March 2, 1984

Drug Marketing; Zeneca sues Eli Lilly, Claiming Misleading Promotion of Evista

March 12, 1999

NCAB Cancer Centers committee recommends Ratio Cap To Limit Growth of Largest Grants

February 14, 1992

USC, Wisconsin Get Construction Grants Totaling $1.5 Million

March 23, 1990

Cooper, Frederickson Formally Named To Top Health, NIH Positions

April 25, 1975

Hopkins Oncology Center Renamed To Honor Sidney Kimmel

May 10, 2002